Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
Evaluating Newly Approved Drugs for Multidrug-resistant TB
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Médecins Sans Frontières, France
- Target Recruit Count
- 754
- Registration Number
- NCT02754765
- Locations
- 🇵🇪
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
🇰🇿National Center for Tuberculosis Problems, Almaty, Kazakhstan
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 12
- Registration Number
- NCT02700347
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore, Singapore
Treatment Shortening of MDR-TB Using Existing and New Drugs
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT02619994
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 18
- Registration Number
- NCT02602509
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 672
- Registration Number
- NCT02581527
- Locations
- 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵GENETUP, National Anti-TB Association, Kathmandu, Nepal
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 147
- Registration Number
- NCT02554318
The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02477852
- Locations
- 🇨🇳
Beijing chest hospital, Beijing, Beijing, China
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 154
- Registration Number
- NCT02454205
- Locations
- 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.